Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma

PURPOSE: This phase II study evaluated the safety and clinical activity of pazopanib, a potent and mutlitargeted tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFRs)-1, -2 and -3, platelet-derived growth factor receptor (PDGFR)-α and β, and cKit, in combination wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fruehauf, John P., El-Masry, Monica, Osann, Katherine, Parmakhtiar, Basmina, Yamamoto, Maki, Jakowatz, James G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060847/
https://www.ncbi.nlm.nih.gov/pubmed/29943192
http://dx.doi.org/10.1007/s00280-018-3624-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060847/
https://www.ncbi.nlm.nih.gov/pubmed/29943192
http://dx.doi.org/10.1007/s00280-018-3624-6

Ejemplares similares